ArticlePloS one2025
Burden of liver cancer resulting from different etiologies in China from 1990 to 2021 and prediction to 2031.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer (LC) imposes a considerable disease burden in China, with diverse causes contributing to varying proportions of LC cases. Adjusting future public health strategies for the allocation of resources to interventions aimed at different causes of LC is a subject that demands resolution in order to maximize health benefits. Employing the Global Burden of Disease (GBD) 2021, we analyzed the burden of LC in China attributed to different causes. Utilize joinpoint to evaluate the trend of the disease burden of LC. The Bayesian model for age-period-cohort (BAPC) was adopted to forecast the burden. The overall trend of the age-standardized rates of incidence, mortality, and disability-standardized life years (ASIR, ASMR, and ASDR) of LC were descend in China from 1990 to 2021. HBV, HCV, alcohol and non-alcoholic steatohepatitis (NASH) constitute the four principal causes of the LC burden. The ASIR, ASMR, and ASDR of LC caused by HBV and HCV showed a downward trend. The ASIR of LC caused by alcohol and NASH were associated with an increased. It was anticipated that the burden of ASIR and ASMR for male, female, and the entire population in China will persistently decline until 2031. In conclusion, the burden of LC has displayed a downward trend in China from 1990 to 2021; HBV, HCV, alcohol, and NASH were the main causes of LC; the burden of LC is expected to further decline by 2031.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.